The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The 3 T MRI results confirmed the relaxivity of the NPs (r 1 = 6.13 mM -1S -1, r 2 = 36.89 mM -1S -1). Results: The Fe 3O 2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe 3O 2 nanoparticle drug delivery system (Fe 3O 2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Select the file that you have just downloaded and select import option Reference Manager (RIS).
Tea mr contrast agent download#
Available fromĬlick on Go to download the file. Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T 1-T 2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics. Gao L, Yu J, Liu Y, Zhou J, Sun L, Wang J, Zhu J, Peng H, Lu W, Yu L, Yan Z, Wang Y. Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai 201203, China. Key Laboratory of Polar Materials and Devices, Ministry of Education, School of Information Science and Technology, East China Normal University, Shanghai 200241, China.ģ. Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.Ģ. Lipeng Gao 1, Jing Yu 1, Yang Liu 1, Jinge Zhou 1, Lei Sun 1, Jing Wang 1, Jianzhong Zhu 1, Hui Peng 2, Weiyue Lu 3, Lei Yu 1, Zhiqiang Yan 1, Yiting Wang 1ġ. Research Paper Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T 1-T 2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics
0 kommentar(er)
